http://www.proactiveinvestors.com.au Proactiveinvestors RSS feed en Thu, 24 May 2018 20:05:22 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Grant of European patent for Moditope platform ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180523070012_13651335/ Wed, 23 May 2018 16:00:12 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180523070012_13651335/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180511131100_13638301/ Fri, 11 May 2018 22:11:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180511131100_13638301/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180509101218_13634421/ Wed, 09 May 2018 19:12:18 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180509101218_13634421/ <![CDATA[RNS press release - Result of the Open Offer and PDMR Shareholdings ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180508070009_13631783/ Tue, 08 May 2018 16:00:09 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180508070009_13631783/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180423124304_13614798/ Mon, 23 Apr 2018 21:43:04 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180423124304_13614798/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180420163241_13613392/ Sat, 21 Apr 2018 01:32:41 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180420163241_13613392/ <![CDATA[RNS press release - Result of Placing and Subscription and PDMR ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180418142900_13609672/ Wed, 18 Apr 2018 23:29:00 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180418142900_13609672/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180418110528_13609338/ Wed, 18 Apr 2018 20:05:28 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180418110528_13609338/ <![CDATA[RNS press release - Price Monitoring Extension ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180418110015_13609326/ Wed, 18 Apr 2018 20:00:15 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180418110015_13609326/ <![CDATA[RNS press release - Technology acquired from University of Nottingham ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180418070005_13608475/ Wed, 18 Apr 2018 16:00:05 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180418070005_13608475/ <![CDATA[RNS press release - Manufacturing agreement with The PolyPeptide Group ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180403070011_13588469/ Tue, 03 Apr 2018 16:00:11 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180403070011_13588469/ <![CDATA[RNS press release - Scancell to present at the Calculus Investor Forum ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180216113001_13536395/ Fri, 16 Feb 2018 22:30:01 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180216113001_13536395/ <![CDATA[RNS press release - Hardman Res. - Validating multiple opportunities ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180215071501_13534125/ Thu, 15 Feb 2018 18:15:01 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180215071501_13534125/ <![CDATA[RNS press release - Collaboration agreement with ISA Pharmaceuticals ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180215070004_13533776/ Thu, 15 Feb 2018 18:00:04 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180215070004_13533776/ <![CDATA[RNS press release - Publication highlights potential of SCIB1 therapy ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180212070003_13528872/ Mon, 12 Feb 2018 18:00:03 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180212070003_13528872/ <![CDATA[RNS press release - European patent application allowed for grant ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180209070003_13527281/ Fri, 09 Feb 2018 18:00:03 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180209070003_13527281/ <![CDATA[RNS press release - Scancell member of team shortlisted for CRUK award ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180208070006_13525658/ Thu, 08 Feb 2018 18:00:06 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180208070006_13525658/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180201070013_13517268/ Thu, 01 Feb 2018 18:00:13 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180201070013_13517268/ <![CDATA[RNS press release - Half-year Report ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180130070003_13513700/ Tue, 30 Jan 2018 18:00:03 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180130070003_13513700/ <![CDATA[RNS press release - Scancell to collaborate with BioNTech ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180109070002_13489184/ Tue, 09 Jan 2018 18:00:02 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20180109070002_13489184/ <![CDATA[RNS press release - Scancell and CRUK to advance cancer immunotherapy ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20171214070003_13464840/ Thu, 14 Dec 2017 18:00:03 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20171214070003_13464840/ <![CDATA[RNS press release - Result of AGM ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20171011094437_13393109/ Wed, 11 Oct 2017 19:44:37 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20171011094437_13393109/ <![CDATA[RNS press release - Directorate Change ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20171010070004_13391130/ Tue, 10 Oct 2017 17:00:04 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20171010070004_13391130/ <![CDATA[RNS press release - Notice of AGM ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170914070007_13362276/ Thu, 14 Sep 2017 16:00:07 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170914070007_13362276/ <![CDATA[RNS press release - Final Results ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170913070004_13360699/ Wed, 13 Sep 2017 16:00:04 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170913070004_13360699/ <![CDATA[RNS press release - Presents Moditope Data at Immunotherapy Conference ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170911070006_13357576/ Mon, 11 Sep 2017 16:00:06 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170911070006_13357576/ <![CDATA[RNS press release - Oncimmune and Scancell Present Autoantibodies Data ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170829070008_13343348/ Tue, 29 Aug 2017 16:00:08 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170829070008_13343348/ <![CDATA[RNS press release - Continued Progress on SCIB1 ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170711070002_13290208/ Tue, 11 Jul 2017 16:00:02 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170711070002_13290208/ <![CDATA[RNS press release - DNA ImmunoBody Patent Granted in Europe ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170626070006_13272200/ Mon, 26 Jun 2017 16:00:06 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170626070006_13272200/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170522125915_13233922/ Mon, 22 May 2017 21:59:15 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170522125915_13233922/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170519144719_13232317/ Fri, 19 May 2017 23:47:19 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170519144719_13232317/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170519070007_13231218/ Fri, 19 May 2017 16:00:07 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170519070007_13231218/ <![CDATA[RNS press release - Results of Placing ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170511120944_13222581/ Thu, 11 May 2017 21:09:44 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170511120944_13222581/ <![CDATA[RNS press release - Proposed Placing to Raise up to £5.0 million ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170511070014_13221756/ Thu, 11 May 2017 16:00:14 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170511070014_13221756/ <![CDATA[RNS press release - Change of Registered Office ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170413123940_13194183/ Thu, 13 Apr 2017 21:39:40 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170413123940_13194183/ <![CDATA[RNS press release - Immuno-Oncology Summit Europe 2017 ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170320070010_13163661/ Mon, 20 Mar 2017 18:00:10 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170320070010_13163661/ <![CDATA[RNS press release - Hardman Research: SCIB development update ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170313071502_13155726/ Mon, 13 Mar 2017 18:15:02 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170313071502_13155726/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170301070023_13142845/ Wed, 01 Mar 2017 18:00:23 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20170301070023_13142845/ <![CDATA[RNS press release - Results of AGM ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20161018174247_013005346/ Wed, 19 Oct 2016 03:42:47 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20161018174247_013005346/ <![CDATA[RNS press release - Preparing SCIB2 for clinical study in lung cancer ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20161010070008_012994561/ Mon, 10 Oct 2016 17:00:08 +1100 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20161010070008_012994561/ <![CDATA[RNS press release - Notice of AGM - Amendment ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160923172418_012977726/ Sat, 24 Sep 2016 02:24:18 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160923172418_012977726/ <![CDATA[RNS press release - Notice of AGM ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160923152839_012977530/ Sat, 24 Sep 2016 00:28:39 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160923152839_012977530/ <![CDATA[RNS press release - Final Results ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160916070006_012968166/ Fri, 16 Sep 2016 16:00:06 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160916070006_012968166/ <![CDATA[RNS press release - Appointment of Non-Executive Director ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160822070008_012938499/ Mon, 22 Aug 2016 16:00:08 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160822070008_012938499/ <![CDATA[RNS press release - Eurogentec manufacturing agreement ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160721070008_012900608/ Thu, 21 Jul 2016 16:00:08 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160721070008_012900608/ <![CDATA[News - Scancell turns to Belgian group to replenish vaccine stocks ]]> http://www.proactiveinvestors.com.au/companies/news/128453/scancell-turns-to-belgian-group-to-replenish-vaccine-stocks-128453.html Scancell Holdings Plc (LON:SCLP) will use Belgian group Eurogentec to manufacture a new batch of its SCIB1 ImmunoBody vaccine.

Scancell wants the drugs for a US clinical study of SCIB1 in combination with a checkpoint inhibitor that is expected to commence in 2017. 

It had to withdraw its stocks of SCIB1 in June after they went out of date having been held for seven years.

Once the US trial is completed, after around 9-12 months, the batch of SCIB1 will also be available to recommence dosing of patients in the long-term extension of a keenly watched Phase I/II clinical study in skin cancer. 

Eurogentec is a contract manufacturer that produces clinical trial and commercial biopharmaceutical material for all major markets including the US and Europe.

Richard Goodfellow, Scancell’s chief executive, said: "We are delighted to be working with Eurogentec, a world class manufacturer, to provide the new batch of SCIB1 material. 

“As can be seen from the latest data from our Phase 1/2 clinical trial, SCIB1 continues to deliver compelling survival data in patients with resected stage III/IV melanoma.

“This new supply will not only be used in our upcoming US checkpoint inhibitor combination trial, but also enable us to recommence treating patients in the long-term extension of the Phase 1/2 study. 

"Access to Eurogentec's expertise and proprietary manufacturing processes has the potential to substantially increase the yields of SCIB1 and fast-track the scale-up that will be required for future Phase III and commercial supply."

]]>
Thu, 21 Jul 2016 08:38:00 +1000 http://www.proactiveinvestors.com.au/companies/news/128453/scancell-turns-to-belgian-group-to-replenish-vaccine-stocks-128453.html
<![CDATA[RNS press release - Extension to Ichor Commercial Option ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160720070007_012898799/ Wed, 20 Jul 2016 16:00:07 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160720070007_012898799/ <![CDATA[News - Scancell extends commercial licence with Ichor ]]> http://www.proactiveinvestors.com.au/companies/news/128383/scancell-extends-commercial-licence-with-ichor-128383.html Cancer immunotherapy group Scancell Holdings Plc (LON:SCLP) has extended its commercial licence of Ichor Medical System’s electroporation delivery system, TriGrid for a further two years.

Scancell will continue to use Ichor’s system in conjunction with its flagship melanoma vaccine SCIB1.

TriGrid allows for the genetic manipulation of a cell by using pulses of electricity to momentarily open the pores of the cell membrane.

"Ichor's proprietary TriGrid electroporation delivery system remains central to our studies on SCIB1 and in particular, to our upcoming US clinical study of SCIB1 in combination with a checkpoint inhibitor, expected to commence in 2017,” said chief executive Richard Goodfellow.

In exchange, Scancell has granted a partial two-year waiver over the lock-up which prohibited the sale of Tranche 2 shares, as originally announced in July 2009 and extended in July 2014.

Subject to exercise of the Tranche two share options, Ichor will remain under an orderly market agreement requiring any sale during that two year period to be effected through Scancell's brokers.  

]]>
Wed, 20 Jul 2016 07:19:00 +1000 http://www.proactiveinvestors.com.au/companies/news/128383/scancell-extends-commercial-licence-with-ichor-128383.html
<![CDATA[News - Scancell’s cancer vaccine programme boosted by scientific review ]]> http://www.proactiveinvestors.com.au/companies/news/128135/scancells-cancer-vaccine-programme-boosted-by-scientific-review-128135.html The scientific community have highlighted the potential of Scancell Holdings Plc’s (LON:SCLP) in-development cancer vaccines.

Scancell’s technology – which promises a completely new class of immuno-oncology therapeutics – has been peer reviewed in a scientific journal.

The report, in the Autophagy journal, discussed Scancell's pre-clinical supporting the innovation and potential of the company’s Moditope platform.

Scancell’s chief scientific officer Professor Lindy Durrant is lead author of the review, which discusses the concept that citrullinated peptides produced during autophagy offer attractive vaccine targets for cancer therapy.

Data described in the review - which had been separately published in another peer-reviewed journal – showed that a single immunization with Moditope resulted in long-term survival in up to 90% of mice.

“Moditope has a unique mechanism of action that overcomes the immune suppression induced by tumour cells, allowing T cells to seek out and kill tumours that would otherwise be hidden from the immune system,” Durrant said in a statement.

“We believe this platform has the potential to develop a new class of immuno-oncology therapeutics and look forward to progressing our first vaccine into the clinic as soon as possible."

It is expected that the first clinical trial coming from the platform will target patients with triple negative breast cancer, ovarian cancer and osteosarcoma.

]]>
Wed, 13 Jul 2016 07:25:00 +1000 http://www.proactiveinvestors.com.au/companies/news/128135/scancells-cancer-vaccine-programme-boosted-by-scientific-review-128135.html
<![CDATA[RNS press release - SCIB1 compelling survival data in melanoma ]]> http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160706070006_012881597/ Wed, 06 Jul 2016 16:00:06 +1000 http://www.proactiveinvestors.com.au/companies/rns/3362/LSE20160706070006_012881597/